Arbaclofen placarbil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Arbaclofen placarbil
Arbaclofen placarbil.svg
Clinical data
  • N/A
ATC code none
Legal status
Legal status
  • Development terminated
CAS Number 847353-30-4
PubChem (CID) 11281011
ChemSpider 9456008
KEGG D08861 YesY
ECHA InfoCard 100.221.150
Chemical and physical data
Formula C19H26ClNO6
Molar mass 399.86 g/mol
3D model (Jmol) Interactive image

Arbaclofen placarbil (ar-BAC-loe-fen pla-KAR-bil, also known as XP19986) is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.[1]

See also[edit]